{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:04:04Z","timestamp":1784891044687,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Anhui Medical College and Scientific research project of Anhui Provincial Colleges and Universities."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-022-04509-w","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:03:14Z","timestamp":1670349794000},"page":"5547-5557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["IL-2\/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K\/AKT and ERK1\/2 pathways"],"prefix":"10.1007","volume":"149","author":[{"given":"Liwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"issue":"4","key":"4509_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T et al (2018) IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36(4):346\u2013351","journal-title":"Nat Biotechnol"},{"issue":"8","key":"4509_CR2","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2008-02-135715","volume":"112","author":"J Barbi","year":"2008","unstructured":"Barbi J, Cummings HE, Lu B et al (2008) PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells. Blood 112(8):3048\u20133051","journal-title":"Blood"},{"issue":"6","key":"4509_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero R, Sektioglu IM, Garbi N et al (2015) Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 16(6):609\u2013617","journal-title":"Nat Immunol"},{"issue":"6","key":"4509_CR4","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow MT, Ozga AJ, Servis RL et al (2019) Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50(6):1498\u20131512","journal-title":"Immunity"},{"issue":"5","key":"4509_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/2326-6066.CIR-13-0084","volume":"1","author":"E Clancy-Thompson","year":"2013","unstructured":"Clancy-Thompson E, King LK, Nunnley LD et al (2013) Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunol Res 1(5):332\u2013339","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"4509_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/JLB.1MR0520-746R","volume":"108","author":"E Donnadieu","year":"2020","unstructured":"Donnadieu E, Dupr\u00e9 L, Pinho LG et al (2020) Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. J Leukoc Biol 108(4):1067\u20131079","journal-title":"J Leukoc Biol"},{"issue":"1","key":"4509_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1034\/j.1600-065X.2002.18813.x","volume":"188","author":"G Dranoff","year":"2002","unstructured":"Dranoff G (2002) GM-CSF-based cancer vaccines. Immunol Rev 188(1):147\u2013154","journal-title":"Immunol Rev"},{"issue":"4","key":"4509_CR500","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jcyt.2014.12.002","volume":"17","author":"T Gargett","year":"2015","unstructured":"Gargett T, Brown MP (2015) Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy 17(4):487\u2013495","journal-title":"Cytotherapy"},{"issue":"16","key":"4509_CR8","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2008-08-175141","volume":"114","author":"CR Geest","year":"2009","unstructured":"Geest CR, Buitenhuis M, Groot Koerkamp MJ et al (2009) Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34+-derived neutrophil progenitors. Blood 114(16):3402\u20133412","journal-title":"Blood"},{"issue":"9","key":"4509_CR9","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019Connor RS et al (2018) Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol Res 6(9):1100\u20131109","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"4509_CR10","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.4049\/jimmunol.1103706","volume":"188","author":"W Huang","year":"2012","unstructured":"Huang W, Hu K, Luo S et al (2012) Herpes simplex virus type 2 infection of human epithelial cells induces CXCL9 expression and CD4+ T cell migration via activation of p38-CCAAT\/enhancer-binding protein-\u03b2 pathway. J Immunol 188(12):6247\u20136257","journal-title":"J Immunol"},{"issue":"3","key":"4509_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/1061186X.2018.1440400","volume":"27","author":"K Li","year":"2019","unstructured":"Li K, Tian H (2019) Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target 27(3):244\u2013256","journal-title":"J Drug Target"},{"issue":"2","key":"4509_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/imt-2020-0062","volume":"13","author":"L Liu","year":"2021","unstructured":"Liu L, Yang M, Xu Q et al (2021) Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions. Immunotherapy 13(2):113\u2013123","journal-title":"Immunotherapy"},{"key":"4509_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","volume":"17","author":"NR Maimela","year":"2019","unstructured":"Maimela NR, Liu S, Zhang Y (2019) Fates of CD8+ T cells in tumor microenvironment. Comput Structural Biotechnol J 17:1\u201313","journal-title":"Comput Structural Biotechnol J"},{"issue":"5","key":"4509_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/00002371-200109000-00002","volume":"24","author":"S Mocellin","year":"2001","unstructured":"Mocellin S, Wang E, Marincola FM (2001) Cytokines and immune response in the tumor microenvironment. J Immunother 24(5):392\u2013407","journal-title":"J Immunother"},{"issue":"2","key":"4509_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.eururo.2011.10.035","volume":"61","author":"KA Oldham","year":"2012","unstructured":"Oldham KA, Parsonage G, Bhatt RI et al (2012) T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur Urol 61(2):385\u2013394","journal-title":"Eur Urol"},{"issue":"1","key":"4509_CR16","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41467-019-12901-3","volume":"11","author":"G Parisi","year":"2020","unstructured":"Parisi G, Saco JD, Salazar FB et al (2020) Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun 11(1):660\u2013667","journal-title":"Nat Commun"},{"issue":"3","key":"4509_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17(3):147\u2013167","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4509_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I et al (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy. Cell 170(6):1109-1119.e10","journal-title":"Cell"},{"key":"4509_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi Y, Liu C, Roberts A et al (2006) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know. Cell Res 16:126\u2013133","journal-title":"Cell Res"},{"key":"4509_CR20","unstructured":"Sow I (2015) Migratory properties of IL-2 and IL-15 activated natural killer cells in dendritic cells and tumor microenvironments. FGS\u2014Electronic Theses and Practica [25327]"},{"key":"4509_CR21","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3389\/fimmu.2018.02159","volume":"9","author":"KH Susek","year":"2018","unstructured":"Susek KH, Karvouni M, Alici E, Lundqvist A (2018) The role of CXC chemokine receptors 1\u20134 on immune cells in the tumor microenvironment. Front Immunol 9:2159","journal-title":"Front Immunol"},{"key":"4509_CR22","unstructured":"The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions"},{"key":"4509_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejca.2016.12.031","volume":"75","author":"JK Tietze","year":"2017","unstructured":"Tietze JK, Angelova D, Heppt MV et al (2017) The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. Eur J Cancer 75:268\u2013279","journal-title":"Eur J Cancer"},{"issue":"11","key":"4509_CR24","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/intimm\/5.11.1483","volume":"5","author":"H Van de Velde","year":"1993","unstructured":"Van de Velde H, Lorr\u00e9 K, Bakkus M et al (1993) CD45RO+ memory T cells but not CD45RA+ naive T cells can be efficiently activated by remote co-stimulation with B7. Int Immunol 5(11):1483\u20131487","journal-title":"Int Immunol"},{"issue":"11","key":"4509_CR25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/2326-6066.CIR-16-0042","volume":"4","author":"XX Wei","year":"2016","unstructured":"Wei XX, Chan S, Kwek S et al (2016) Systemic GM-CSF recruits effector T cells into the tumor microenvironment in localized prostate cancer. Cancer Immunol Res 4(11):948\u2013958","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"4509_CR26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y et al (2021) Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II Trial. Clin Cancer Res 27(4):1003\u20131011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4509_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/imt-2016-0141","volume":"9","author":"WL Yan","year":"2017","unstructured":"Yan WL, Shen KY, Tien CY et al (2017) Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy 9(4):347\u2013360","journal-title":"Immunotherapy"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04509-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04509-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04509-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:06:17Z","timestamp":1689768377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04509-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4509"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04509-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}